ZYLOXTB (02190) announced that for the fiscal year ending December 31, 2025 (the reporting period), the net profit attributable to the company's equity holders is expected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% compared to RMB 100.3 million for the year ended December 31, 2024. Furthermore, the Group's revenue for the reporting period is anticipated to surpass RMB 1.05 billion, marking an approximate 34.6% increase from the RMB 780 million recorded in the prior year. This significant improvement in performance is primarily driven by three key factors: 1) continued robust growth in domestic sales of several flagship products, including the Qilin Blood Flow Diverter, neurovascular guidewires, the UltraFree Drug-Eluting PTA Balloon Dilatation Catheter (UltraFree DCB), and the Swan Venous Radiofrequency Ablation Catheter; 2) international sales more than doubling year-on-year due to successful market expansion into multiple regions; and 3) a relatively stable gross profit margin, coupled with continuously improving operational efficiency.